Regarding BTC, the FDA has recently approved drugs that inhibit IDH1 and FGFR2, genes that are most frequently altered in intrahepatic CCA, but which have also demonstrated efficacy in extrahepatic biliary tract tumours with the same genetic alteration. Here, IDH1 is linked to cholangiocarcinoma.